Abivax Achieves Key Milestone in Phase 3 ABTECT Trial Enrollment
Portfolio Pulse from
Abivax has reached 82% of its target enrollment in the Phase 3 ABTECT trial for obefazimod, a treatment for ulcerative colitis. The trial is expected to complete enrollment by Q2 2025.
January 09, 2025 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Abivax has achieved 82% enrollment in its Phase 3 ABTECT trial for obefazimod, a treatment for ulcerative colitis, with full enrollment expected by Q2 2025.
The achievement of 82% enrollment in the Phase 3 trial is a significant milestone for Abivax, indicating progress in the development of obefazimod. This could positively impact investor sentiment and the stock price in the short term as it shows the company is on track with its clinical trial timeline.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90